Nuvectis Pharma (NVCT) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
Meeting called to order with directors and independent auditors introduced in attendance remotely.
Legal counsel and inspector of elections roles identified; agenda included voting on business matters described in the proxy statement.
Overview of voting outcomes
Quorum confirmed with majority of shares represented as of April 13, 2026.
Voting conducted on two items: election of a director and ratification of the independent auditor.
Election of director for a term until the 2029 annual meeting approved.
Ratification of Kesselman & Kesselman as independent auditor for 2026 fiscal year approved.
Complete voting results to be filed in Form 8-K with the SEC and posted on the company website.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Nuvectis Pharma
- Advancing late-stage precision therapies for complement diseases and cancer with strong clinical data.NVCT
Corporate presentation - Q2 2026 net loss was $7.0M; $115M raised in July extends cash runway into 1H 2029.NVCTQ2 2026
- Late-stage NXP100 and NXP200 in-licensed, expanding pipeline in complement and oncology.NVCTStatus update
- NXP900 demonstrates potent, selective SRC inhibition and promising safety in early clinical trials.NVCTH.C. Wainwright 4th Annual BioConnect Investor Conference
- NXP900 shows promise in overcoming resistance in solid tumors and NSCLC with strong early data.NVCTCorporate presentation
- Q1 2026 net loss was $6.1M as NXP900 clinical progress drove higher R&D and G&A costs.NVCTQ1 2026
- Vote on director election and auditor ratification at the June 2026 annual meeting.NVCTProxy filing
- Annual meeting to vote on director election and auditor ratification, with strong governance.NVCTProxy filing
- NXP900’s oral regimen targets resistance and unmet needs in NSCLC with a novel, well-tolerated approach.NVCTKOL Event